Estrogene receptor (ER) is a predictive marker for anti-estrogen treatment in breast cancer. The American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) recommends that the ER status of patients is determined on all invasive breast cancers and breast cancer recurrences.
The APP automatically provides ER positivity scores in tumor, by analyzing the whole slide (both resections and needle core biosies) to:
1) detecting patient material, eliminating control material and artifacts
2) identifying tumor areas, eliminating preinvasive areas
3) scoring the invasive tumor, providng summary metrics such as % positive, H-score and Allred score.
Application can be launched from Sectra's pathology image window: Yes
Results will be shown in Sectra's pathology image window: Yes
Ask your Sectra representative which version of the Sectra PACS is compatible with the highlighted integration standards.
Contact usAre you interested in learning more? Please do not hesitate to get in touch with us at Sectra.
The application content is provided by the respective AI vendors.
